news
We unravel disease mechanisms
news
InnoSIGN receives grant of almost €700K for ovarian cancer multicenter trial
news
Institut Gustave Roussy: OncoSIGNal predicts resistance to AR targeted drugs in mCR prostate cancer
events
Identifying mutation-independent signaling pathway activation in molecular subtypes of triple negative breast cancers
events
Meet InnoSIGN at Association for Molecular Pathology (AMP) 2023
events